Arcus Biosciences Inc (RCUS) News

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR) and...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Gilead Sciences’ window to exercise its option to casdatifan has expired; $150 million financing enables Arcus to independently advance its...

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...

Form 8-K - Current report

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily (BID) casdatifan monotherapy cohort of the Phase 1/1b...

Form 4 - Statement of changes in beneficial ownership of securities

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...

Form 3 - Initial statement of beneficial ownership of securities